Because HMGB1 was similarly accumulated in patients with COVID-19 [184], these TN/RBM-reactive mAbs might simultaneously block harmful TN/HMGB1 interaction and resultant immunosuppression, and suppress possible SARS-CoV-2/ACE2 interaction to inhibit GM-CSF production in patients with COVID-19 and other lethal infections [71]. This evidence concerns the gene HMGB1 and infection.